Imunon director granted 11,148 shares as board fees

Dentzer James E reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Dentzer James E reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. director James E. Dentzer received a grant of 11,148 shares of Common Stock as part of his board compensation. The shares were granted on May 22, 2026 at a reference price of $2.20 per share in lieu of cash for a portion of his board fees. Following this award, Dentzer directly holds 14,963 shares of Imunon common stock.

Insider Trade Summary

Grant/Award: 11,148 shares

Grant/Award 1 txn

Insider Dentzer James E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,148	$2.20	$25K

Holdings After Transaction: Common Stock — 14,963 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of board fees

Key Figures

Shares granted: 11,148 shares Transaction price: $2.20 per share Shares held after: 14,963 shares

3 metrics

Shares granted 11,148 shares Common Stock grant on May 22, 2026

Transaction price $2.20 per share Reference price for the 11,148-share grant

Shares held after 14,963 shares Total direct holdings following the grant

Key Terms

Grant, award, or other acquisition, Common Stock, in lieu of cash

3 terms

Grant, award, or other acquisition financial

"transaction code description "Grant, award, or other acquisition""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

in lieu of cash financial

"Stock granted in lieu of cash for portion of board fees"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Imunon (IMNN) director James E. Dentzer report?

James E. Dentzer reported receiving 11,148 shares of Imunon Common Stock. The shares were granted as part of his board compensation in lieu of cash for a portion of his board fees, reflecting a non-cash equity award rather than an open-market trade.

On what date was the Imunon (IMNN) stock grant to James E. Dentzer made?

The stock grant to James E. Dentzer was made on May 22, 2026. This grant of 11,148 Common Stock shares was reported as a compensation-related award, categorized as a grant or other acquisition under the Form 4 transaction code A.

How many Imunon (IMNN) shares does James E. Dentzer hold after this Form 4 transaction?

After the reported grant, James E. Dentzer directly holds 14,963 Imunon Common Stock shares. This total includes the 11,148 shares awarded on May 22, 2026, which were granted in lieu of cash for a portion of his board fees.

Was the Imunon (IMNN) Form 4 transaction by James E. Dentzer a market purchase or sale?

The transaction was not a market purchase or sale. It was classified as a grant or award acquisition, with 11,148 Common Stock shares granted in lieu of cash for part of Dentzer’s board fees, reflecting routine equity compensation.

What price per share is shown for the Imunon (IMNN) stock granted to James E. Dentzer?

The filing shows a transaction price of $2.20 per share for the 11,148 Common Stock shares. This price is the reference transaction value reported on the Form 4 for the compensation-related equity grant on May 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dentzer James E

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		11,148(1)	A	$2.2	14,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees

Remarks:

On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

	/s/ Susan Eylward, Attorney-in-Fact for James E. Dentzer	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)